The Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE), formed in early 2020, is a consortium of 18 academic institutions working together to create a powerful clinical-genomic platform to interrogate and address data gaps that have arisen with increased genomic testing in the clinical management of prostate cancer.
Over the last decade, advancements in genomic sequencing technologies have allowed for a deeper understanding of the molecular complexity of metastatic castrate-resistant prostate cancer (mCRPC). Many potentially actionable alterations are now identified, fueling biomarker-based clinical trials of novel molecularly targeted agents as well as standard therapies.
With this shifting paradigm and advancements in technology, there will be a rise in availability, breadth, and scope of genomic data derived from CLIA-based testing platforms. Linkage of this data with granular patient outcomes can be leveraged to improve our understanding of the molecular mechanisms that lead to variable clinical outcomes across prostate cancer disease states over time, identify additional subgroups of patients whose tumors are more vulnerable to specific therapies, and help guide decisions of optimal sequencing of therapies in prostate cancer.
To investigate the outcomes of patients with advanced prostate cancer who have genomic and molecular profiling information in order to bridge the knowledge gap between real-world genomic data and clinical outcomes in patients with advanced prostate cancer.
To better inform future clinical care and precision medicine approaches by:
- establishing a large, diverse, inclusive, and well-annotated repository of completely de-identified clinical and genomic patient data that is linked to clinical characteristics and disease-related outcomes.
- investigating prognostic and potentially predictive biomarkers in patients with advanced prostate cancer treated with approved therapies including genomic, transcriptomic, and proteomic biomarkers.